Neuroblastoma Clinical Trials

39 studies are recruiting for neuroblastoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 2

1. NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

   This is a phase II study looking at patient response to treatment with the combination dinutuximab, temozolomide, irinotecan, and GM-CSF.

   Stage

   Phase 2

   Ages

   1 to 31

   Site

   Children's Hospital Los Angeles, Los Angeles, California

   Locations

   13 in total

   Run by

   New Approaches to Neuroblastoma Therapy Consortium

   See if you can join NCT06450041 on ClinicalTrials.gov

2. Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma

   This research is being done to investigate a treatment regimen of Irinotecan, Temozolomide, and Sargramostin, and an immunotherapy called Naxitamab and whether giving Naxitamab more slowly reduces the side effects for participants with relapsed or refractory neuroblastoma. The name of the study dru…

   Stage

   Phase 1

   Ages

   1 to 30

   Site

   Boston Children's Hospital, Boston, Massachusetts

   Locations

   2 in total

   Run by

   Steven DuBois, MD

   See if you can join NCT07027748 on ClinicalTrials.gov

3. Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors

   Hematopoietic stem cell transplantation can cure patients with blood cancer and other underlying diseases. αβ-T cell and B cell depletion has been introduced to decrease GVHD and PTLD and has demonstrated effectiveness for hematologic malignancies and non-malignant diseases additionally increasing …

   Stage

   Phase 1

   Ages

   0 to 25

   Site

   University of Florida, Gainesville, Florida

   Run by

   University of Florida

   See if you can join NCT06625190 on ClinicalTrials.gov

4. Familial Investigations of Childhood Cancer Predisposition

   NOTE: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receive results many years from the time they enroll. If you are interested in clinical testing please consider seeing a local genetic counselor …

   Stage

   Not phased

   Ages

   Any age

   Site

   St. Jude Children's Research Hospital, Memphis, Tennessee

   Run by

   St. Jude Children's Research Hospital

   See if you can join NCT03050268 on ClinicalTrials.gov

5. Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

   The purpose of this research study is to find how active and safe 131 I-MIBG is in patients with resistant neuroblastoma, malignant pheochromocytoma and malignant paraganglioma.

   Stage

   Phase 2

   Ages

   1 and older

   Site

   Memorial Sloan Kettering Cancer Center, New York, New York

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT00107289 on ClinicalTrials.gov

6. B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

   3CAR is being done to investigate an immunotherapy for patients with solid tumors. It is a Phase I clinical trial evaluating the use of autologous T cells genetically engineered to express B7-H3-CARs for patients ≤ 21 years old, with relapsed/refractory B7-H3+ solid tumors. This study will evaluate…

   Stage

   Phase 1

   Ages

   Up to 21

   Site

   St. Jude Children's Research Hospital, Memphis, Tennessee

   Run by

   St. Jude Children's Research Hospital

   See if you can join NCT04897321 on ClinicalTrials.gov

7. Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors

   The purpose of this study is to test the manufacturing feasibility and safety of intravenous (IV) administration of B7-H3CART in children and young adult subjects with relapsed and/or refractory solid tumors expressing B7-H3 target using a standard 3+3 dose escalation design.

   Stage

   Phase 1

   Ages

   2 to 30

   Site

   Stanford University, Palo Alto, California

   Run by

   Stanford University

   See if you can join NCT06500819 on ClinicalTrials.gov

8. Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies

   Investigators are testing new experimental drug combinations such as the combination of vorinostat, vincristine, irinotecan, and temozolomide in the hopes of finding a drug that may be effective against tumors that have come back or that have not responded to standard therapy. The goals of this stu…

   Stage

   Phase 1

   Ages

   1 to 30

   Site

   New York Medical College, Valhalla, New York

   Run by

   New York Medical College

   See if you can join NCT04308330 on ClinicalTrials.gov

9. Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma

   The body has different ways of fighting infections and disease. No single way seems perfect for fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells. Antibodies are molecules that fight infections and protect your body from diseases caused by …

   Stage

   Phase 1

   Ages

   1 and older

   Site

   Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina

   Locations

   2 in total

   Run by

   UNC Lineberger Comprehensive Cancer Center

   See if you can join NCT03721068 on ClinicalTrials.gov

10. Neuroblastoma Biology Study

    Medical scientists want to find better ways to treat neuroblastoma and to find ways to prevent the tumor from growing back. To do this, they need more information about the characteristics of neuroblastoma cells. Therefore, they want to study samples of neuroblastoma tissues and neuroblastoma and n…

    Stage

    Not phased

    Ages

    0 to 99

    Site

    Children's Hospital Los Angeles, Los Angeles, California

    Locations

    17 in total

    Run by

    New Approaches to Neuroblastoma Therapy Consortium

    See if you can join NCT01587300 on ClinicalTrials.gov

11. Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma

    The goal of this study is to test if the addition of a novel income-poverty targeted supportive care intervention (Pediatric Resource Intervention to Support Equity [Pediatric RISE]) to usual supportive care for low-income children with high-risk neuroblastoma can improve parent- and child-centered…

    Stage

    Not phased

    Ages

    Up to 17

    Site

    Connecticut Children's Medical Center, Hartford, Connecticut

    Locations

    6 in total

    Run by

    Dana-Farber Cancer Institute

    See if you can join NCT06831552 on ClinicalTrials.gov

12. Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma

    The goal of this clinical trial is to determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) of allogeneic expanded γδ T cells when delivered with Dinutuximab, temozolomide, irinotecan, and zoledronate in children with refractory or recurrent neuroblastoma or refractory/ re…

    Stage

    Phase 1

    Ages

    1 and older

    Site

    Children's Healthcare of Atlanta, Atlanta, Georgia

    Run by

    Emory University

    See if you can join NCT05400603 on ClinicalTrials.gov

13. GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma

    This research study combines two different ways of fighting cancer: antibodies and Natural Killer T cells (NKT). Antibodies are types of proteins that protect the body from infectious diseases and possibly cancer. T cells, also called T lymphocytes, are special white blood cells that can kill other…

    Stage

    Phase 1

    Ages

    1 to 21

    Site

    Texas Children's Hospital, Houston, Texas

    Run by

    Baylor College of Medicine

    See if you can join NCT03294954 on ClinicalTrials.gov

14. A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

    This study will expand the types of pediatric cancers being evaluated for response to cabozantinib. The current COG study is restricted to Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, Wilms tumor, and a handful of uncommon tumors. The proposed study will extend this evaluation to tumors that have…

    Stage

    Phase 2

    Ages

    1 to 40

    Site

    Children's Hospital of Alabama/UAB, Birmingham, Alabama

    Locations

    6 in total

    Run by

    Nationwide Children's Hospital

    See if you can join NCT05135975 on ClinicalTrials.gov